c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
Open Access
- 6 June 2020
- Vol. 12 (6), 1489
- https://doi.org/10.3390/cancers12061489
Abstract
The proto-oncogene c-Src is a non-receptor tyrosine kinase playing a key role in many cellular pathways, including cell survival, migration and proliferation. c-Src de-regulation has been observed in several cancer types, making it an appealing target for drug discovery efforts. Recent evidence emphasizes its crucial role not only in promoting oncogenic traits, but also in the acquisition and maintenance of cancer resistance to various chemotherapeutic or molecular target drugs. c-Src modulates epidermal growth factor receptor (EGFR) activation and amplifies its downstream oncogenic signals. In this review, we report several studies supporting c-Src kinase role in the intricate mechanisms of resistance to EGFR tyrosine kinase inhibitors (TKIs). We further highlighted pre- and clinical progresses of combined treatment strategies made in recent years. Several pre-clinical data have encouraged the use of c-Src inhibitors in combination with EGFR inhibitors. However, clinical trials provided controversial outcomes in some cancer types. Despite c-Src inhibitors showed good tolerability in cancer patients, no incontrovertible and consistent clinical responses were recorded, supporting the idea that a better selection of patients is needed to improve clinical outcome. Currently, the identification of biological markers predictive of therapy response and the accurate molecular screening of cancer patients aimed to gain most clinical benefits become decisive and mandatory.Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG2018 grant number 21339, MFAG2018 grant number 21505)
This publication has 105 references indexed in Scilit:
- Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845International Journal of Molecular Sciences, 2013
- Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell linesEuropean Journal of Cancer, 2012
- Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cellsCancer Biology & Therapy, 2011
- Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor GrowthClinical Cancer Research, 2011
- Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximabOncogene, 2010
- Insulin Induces Swelling-dependent Activation of the Epidermal Growth Factor Receptor in Rat LiverOnline Journal of Public Health Informatics, 2010
- Nuclear EGFR contributes to acquired resistance to cetuximabOncogene, 2009
- PI3K/Akt and apoptosis: size mattersOncogene, 2003
- The role of Src family kinases in the normal and neoplastic gastrointestinal tractSurgical Oncology, 1996
- Expression of pp60c-src in human small cell and non-small cell lung carcinomasEuropean Journal of Cancer, 1992